Literature DB >> 20923433

Diurnal cortisol patterns of young male patients with schizophrenia.

Roelie J Hempel1, Joke H M Tulen, Nico J M van Beveren, Christian H Röder, Frank H de Jong, Michiel W Hengeveld.   

Abstract

AIMS: It has been suggested that schizophrenic patients are more vulnerable to stress than healthy persons, and that stressors can trigger a psychotic episode or worsen symptoms. The biological system often studied in relation to stress is the hypothalamic-pituitary-adrenal (HPA) axis, which controls the release of cortisol. We investigated whether the diurnal basal activity of the HPA axis differed between young male patients with schizophrenia and healthy controls.
METHODS: Twenty-seven male patients (mean age 22 ± 5 years) and 38 healthy male control subjects (mean age 22 ± 3 years) were included in the present study. Saliva was sampled at five time points during the day: directly after awakening, 30 min thereafter, and at 12.00 hours, 16.00 hours and 22.00 hours.
RESULTS: The cortisol concentration decreased significantly more during the day in the patient group thanin the control group. Patients also showed a significantly decreased area under the curve with respect to the increase, again indicating that the cortisol concentrations decreased more during the day in patients than in controls. Both the morning increase and the area under the curve with respect to the increase were significantly negatively correlated with negative symptom severity.
CONCLUSIONS: Patients with schizophrenia showed a different daytime sensitivity of the HPA axis. Our findings further suggest that an increase in negative symptom severity is related to a decreased HPA axis sensitivity.
© 2010 The Authors. Psychiatry and Clinical Neurosciences © 2010 Japanese Society of Psychiatry and Neurology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20923433     DOI: 10.1111/j.1440-1819.2010.02121.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  6 in total

Review 1.  The role of cortisol in first episode of psychosis: a systematic review.

Authors:  Evangelos Karanikas; Diomidis Antoniadis; George D Garyfallos
Journal:  Curr Psychiatry Rep       Date:  2014-11       Impact factor: 5.285

2.  Disrupted circadian rhythms in a mouse model of schizophrenia.

Authors:  Peter L Oliver; Melanie V Sobczyk; Elizabeth S Maywood; Benjamin Edwards; Sheena Lee; Achilleas Livieratos; Henrik Oster; Rachel Butler; Sofia I H Godinho; Katharina Wulff; Stuart N Peirson; Simon P Fisher; Johanna E Chesham; Janice W Smith; Michael H Hastings; Kay E Davies; Russell G Foster
Journal:  Curr Biol       Date:  2012-01-19       Impact factor: 10.834

3.  The psychophysiological effects of Tai-chi and exercise in residential schizophrenic patients: a 3-arm randomized controlled trial.

Authors:  Rainbow Tin Hung Ho; Adrian Ho Yin Wan; Friendly So Wah Au-Yeung; Phyllis Hau Yan Lo; Pantha Joey Chung Yue Siu; Cathy Pui Ki Wong; Winnie Yuen Han Ng; Irene Kit Man Cheung; Siu Man Ng; Cecilia Lai Wan Chan; Eric Yu Hai Chen
Journal:  BMC Complement Altern Med       Date:  2014-09-27       Impact factor: 3.659

4.  Hair cortisol, social support, personality traits, and clinical course: differences in schizophrenia and bipolar disorder.

Authors:  Fuzhong Yang; Xiangfei Hong; Jing Tao; Yupeng Chen; Yanbo Zhang; Hua Xiao
Journal:  Brain Behav       Date:  2021-11-13       Impact factor: 2.708

Review 5.  Early interventions in risk groups for schizophrenia: what are we waiting for?

Authors:  Iris E Sommer; Carrie E Bearden; Edwin van Dellen; Elemi J Breetvelt; Sasja N Duijff; Kim Maijer; Therese van Amelsvoort; Lieuwe de Haan; Raquel E Gur; Celso Arango; Covadonga M Díaz-Caneja; Christiaan H Vinkers; Jacob As Vorstman
Journal:  NPJ Schizophr       Date:  2016-03-09

6.  Hair Cortisol Is Associated With Social Support and Symptoms in Schizophrenia.

Authors:  Fuzhong Yang; Xinyi Cao; Xiujia Sun; Hui Wen; Jianyin Qiu; Hua Xiao
Journal:  Front Psychiatry       Date:  2020-09-24       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.